Mental health studies with practical context.

The study compares 25 mg, 10 mg and 1 mg doses of investigational psilocybin (NPX-5), combined with psychotherapy and medical supervision, to assess safety and effectiveness. Dose allocation is by chance; the 1 mg group is a low-dose comparison group.

TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

This study evaluates the safety of psilocybin for people with PTSD.

Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial

Processing Intergenerational Trauma With Psilocybin-Assisted Therapy

A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)

This study evaluates the safety and effectiveness of Psilocybin for people with depression.

This study assesses depression symptoms.

Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder

Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study

A Pilot Study on the Impact of a Psychiatric Consultation-Liaison Intervention in Primary Care Medical Consultations in French Speaking Switzerland (PLIMeC-P): A Mixed Method Randomized Controlled Trial